Efficacy and Safety of New B Cell-Targeted Biologic Agent for the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Metadatos
Mostrar el registro completo del ítemAutor
Gómez Urquiza, José Luis; Romero Béjar, José Luis; Chami-Peña, Sara; Suleiman-Martos, Nora; Cañadas-De La Fuente, Guillermo A.; Molina, Esther; Riquelme Gallego, BlancaEditorial
MDPI
Materia
systemic lupus erythematosus safety biologic treatment efficacy meta-analysis
Fecha
2023-07-23Referencia bibliográfica
Gómez-Urquiza, J.L.; Romero-Bejar, J.L.; Chami-Peña, S.; Suleiman-Martos, N.; Cañadas-De la Fuente, G.A.; Molina, E.; Riquelme-Gallego, B. Efficacy and Safety of New B Cell-Targeted Biologic Agent for the Treatment of Systemic Lupus Erythematosus: A Systematic Review andMeta-Analysis. J. Clin. Med. 2023, 12, 4848. https:// doi.org/10.3390/jcm12144848
Resumen
Background: B cells are central to the pathogenesis of systemic lupus erythematosus
(SLE). We aimed to analyze the efficacy and safety of new B cell-targeted drug therapies for SLE.
Methods: A systematic review of randomized controlled trials (RCTs) and reference lists of relevant
articles published from inception to 2022 were selected from PubMed, Scopus andWeb of Science
databases. Random effects meta-analyses were performed to estimate an overall effect size for the
risk of adverse events (AEs) and serious adverse events (SAEs) with belimumab and tabalumab
treatment. Heterogeneity was assessed using the I2 statistic and meta-regression. Funnel asymmetry
was evaluated using Egger’s test. Results: This study included 13 RCTs, of which three showed high
risk of bias. Egger’s test showed no asymmetry. The risk of SAEs and AEs was lower in the treatment
group with belimumab treatment. The risk of AEs for tabalumab treatment was lower in the treatment
group and lower for SAEs. Conclusion: Belimumab and tabalumab therapies are effective and safe
in the treatment of SLE, although tabalumab does not show sufficient statistical power. Advances
in understanding the underlying mechanisms of SLE will be directed towards correlating clinical
manifestations with specific pathogenic pathways and the development of precision medicine.